Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06028373 · ClinicalTrials.gov registry record · Phase 1
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
A Phase 1 study of Advanced Solid Tumors and B-cell Non-Hodgkin Lymphomas, sponsored by Antengene Biologics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT06028373: Recruiting Phase 1 study of Advanced Solid Tumors and B-cell Non-Hodgkin Lymphomas, sponsored by Antengene Biologics Limited.
NCT06028373 is a Phase 1 study of Advanced Solid Tumors and B-cell Non-Hodgkin Lymphomas that is actively recruiting participants, run by Antengene Biologics Limited. The registered enrollment target is 80 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06028373, a Phase 1 study of Advanced Solid Tumors and B-cell Non-Hodgkin Lymphomas, is actively recruiting participants, sponsored by Antengene Biologics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D（Refered Phase II dose） of ATG-031.
Primary Outcome
Evaluate the safety and tolerability of ATG-031
Conditions Studied
Interventions
- DRUG ATG-031
Study Locations (4)
California
- University of California San Francisco (UCSF) - San Francisco
Colorado
- Regents of the University of Colorado - Aurora
Connecticut
- Yale University - New Haven
Texas
- University of Texas M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT06028373 shows while recruiting
NCT06028373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ATG-031 is the first listed.
NCT06028373 reports a single indexed study location in California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06028373 about?
NCT06028373 is a clinical study titled "A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas". ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or re...
What is the current status of trial NCT06028373?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-12-08. Estimated completion is 2027-06-30.
What conditions does trial NCT06028373 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas.
What interventions are being tested in trial NCT06028373?
The interventions under investigation include: ATG-031 (DRUG).
Who is sponsoring clinical trial NCT06028373?
This trial is sponsored by Antengene Biologics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06028373 being conducted?
This trial has 4 study locations across California, Colorado, Connecticut, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06028373's enrollment target sits among peer trials
80 89th of 144 higher than 56 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI